Table 2.
In silico analysis of gene expression profiles in NB patients from various independent studies showing differential association of CD34 gene levels with NB advanced disease stage and clinical outcomes. The results of these gene expression (RNA sequencing, microarray) studies did not conclusively agree and affirm beneficial or detrimental effects of CD34 expression in NB. Momentous differences were observed in terms of patient cohorts, platform used, MYCN status, and disease status.
| Geo ID | n | OS All |
OS MA |
OS MN |
RFS All |
RFS MA |
RFS MN |
ADSAll | ADSMA | ADSMN |
|---|---|---|---|---|---|---|---|---|---|---|
| GSE16476 | 88 | HW | X | HW | HW | X | HW | X | X | X |
| GSE3446 | 102 | HW | ||||||||
| TARGET161 | 161 | D | D | D | ||||||
| TARGET249 | 249 | LW | HW | LW | HW | HW | LW | X | D | X |
| GSE27608 | 47 | D | ||||||||
| GSE73517 | 105 | X | X | X | ||||||
| NBpreter24 | 24 | X | X | X | ||||||
| GSE49710 | 498 | LW | HW | LW | LW | HW | LW | X | X | X |
| GSE62564 | 498 | LW | LW | LW | LW | X | X | |||
| NB251 | 251 | LW | LW | LW | LW | LW | LW | X | X | X |
| GSE3960 | 101 | X | X | |||||||
| GSE54720 | 23 | D | D | X | ||||||
| GSE13136 | 30 | X | X | |||||||
| GSE45547 | 649 | LW | LW | LW | LW | LW | LW | X | X | D |
| GSE19274 | 100 | X | X | X | ||||||
| GSE16237 | 51 | X | X | X | ||||||
| GSE12460 | 64 | I | X | I | ||||||
| GSE85047 | 283 | HW | HW | HW | HW | LW | LW | X | D | X |
n = number of patients; OS = overall survival; RFS = Relapse-free survival; MA = N-MYC amplified; MN = N-MYC non-amplified; ADS = Advanced disease stage; HW = High is Worse; LW = Low is Worse; D = Direct association; I = Inverse Association; X = no association. Note: Fields left blank had no data available or computed.